Last reviewed · How we verify
Inolimomab (Leukotac)
Inolimomab is a monoclonal antibody that blocks the IL-2 receptor alpha chain (CD25) on T cells to suppress excessive immune activation.
Inolimomab is a monoclonal antibody that blocks the IL-2 receptor alpha chain (CD25) on T cells to suppress excessive immune activation. Used for Graft-versus-host disease (GVHD).
At a glance
| Generic name | Inolimomab (Leukotac) |
|---|---|
| Sponsor | ElsaLys Biotech |
| Drug class | Monoclonal antibody (anti-CD25) |
| Target | CD25 (IL-2 receptor alpha chain) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Inolimomab targets CD25, the alpha subunit of the IL-2 receptor expressed on activated T lymphocytes. By blocking IL-2 signaling through this receptor, the drug inhibits T cell proliferation and activation, reducing pathogenic immune responses. This mechanism is intended to control inflammatory and autoimmune conditions driven by overactive T cell responses.
Approved indications
- Graft-versus-host disease (GVHD)
Common side effects
- Infections
- Immunosuppression-related complications
- Infusion reactions
Key clinical trials
- Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease
- Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inolimomab (Leukotac) CI brief — competitive landscape report
- Inolimomab (Leukotac) updates RSS · CI watch RSS
- ElsaLys Biotech portfolio CI